ASCO GUIDELINES Bundle

Hereditary Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475464

Contents of this Issue

Navigation

Page 10 of 11

11 Table 2. Clinical Stage + Pathologic Stage + ER status + Nuclear grade (CPS&EG score) Calculation instructions: Add the points for Clinical Stage + Pathologic Stage + ER status + Nuclear grade to derive a sum (CPS&EG score) between 0 and 6. Stage/feature Points Clinical Stage (AJCC staging 1 ) I 0 IIA 0 IIB 1 IIIA 1 IIIB 2 IIIC 2 Pathologic Stage (AJCC staging 1 ) 0 0 I 0 IIA 1 IIB 1 IIIA 1 IIIB 1 IIIC 2 Receptor status ER negative 2 1 Nuclear grade 3 Nuclear grade 3 1 1 AJCC: American Joint Committee on Cancer (https://cancerstaging.org/Pages/default.aspx) 2 ER: Estrogen receptor; definitions for ER negativity see eligibility criteria section 4.1.4.a 3 In the unlikely situation nuclear grade cannot be determined, regular histologic grade should be used; if only Nottingham overall grade is reported, the Nottingham overall grade must be 9 to be scored as 1 point in the CPS&EG score (http://patholog y.jhu.edu/breast/grade.php). From e New England Journal of Medicine, Tutt ANJ et al, Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer, 384, 2394-2405. Copyright ©2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Hereditary Breast Cancer